References
- Choi CW, Kim BR, Ohn J, Youn SW. The advantage of cyclosporine A and methotrexate rotational therapy in long-term systemic treatment for chronic plaque psoriasis in a real world practice. Ann Dermatol 2017;29:55-60. https://doi.org/10.5021/ad.2017.29.1.55
- Ramirez-Fort MK, Levin AA, Au SC, Gottlieb AB. Continuous versus intermittent therapy for moderate-to-severe psoriasis. Clin Exp Rheumatol 2013;31:S63-S70.
- Kimball AB, Gordon KB, Fakharzadeh S, Yeilding N, Szapary PO, Schenkel B, et al. Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3 years. Br J Dermatol 2012;166:861-872. https://doi.org/10.1111/j.1365-2133.2012.10901.x
- Vilarrasa E, Notario J, Bordas X, Lopez-Ferrer A, Gich IJ, Puig L. ORBIT (Outcome and Retention Rate of Biologic Treatments for Psoriasis): a retrospective observational study on biologic drug survival in daily practice. J Am Acad Dermatol 2016;74:1066-1072. https://doi.org/10.1016/j.jaad.2016.01.037
- Shalom G, Cohen AD, Ziv M, Eran CB, Feldhamer I, Freud T, et al. Biologic drug survival in Israeli psoriasis patients. J Am Acad Dermatol 2017;76:662-669.e1. https://doi.org/10.1016/j.jaad.2016.10.033
- Zweegers J, van den Reek JM, van de Kerkhof PC, Otero ME, Kuijpers AL, Koetsier MI, et al. Body mass index predicts discontinuation due to ineffectiveness and female sex predicts discontinuation due to side-effects in patients with psoriasis treated with adalimumab, etanercept or ustekinumab in daily practice: a prospective, comparative, long-term drug-survival study from the BioCAPTURE registry. Br J Dermatol 2016;175:340-347. https://doi.org/10.1111/bjd.14552
- van den Reek JM, Zweegers J, Kievit W, Otero ME, van Lumig PP, Driessen RJ, et al. 'Happy' drug survival of adalimumab, etanercept and ustekinumab in psoriasis in daily practice care: results from the BioCAPTURE network. Br J Dermatol 2014;171:1189-1196. https://doi.org/10.1111/bjd.13087
- Gniadecki R, Bang B, Bryld LE, Iversen L, Lasthein S, Skov L. Comparison of long-term drug survival and safety of biologic agents in patients with psoriasis vulgaris. Br J Dermatol 2015;172:244-252. https://doi.org/10.1111/bjd.13343
- van den Reek JM, van Lumig PP, Driessen RJ, van de Kerkhof PC, Seyger MM, Kievit W, et al. Determinants of drug survival for etanercept in a long-term daily practice cohort of patients with psoriasis. Br J Dermatol 2014;170:415-424. https://doi.org/10.1111/bjd.12648
- Nickoloff BJ, Stevens SR. What have we learned in dermatology from the biologic therapies? J Am Acad Dermatol 2006;54:S143-S151. https://doi.org/10.1016/j.jaad.2005.10.059
- Puig L, Ruiz-Salas V. Long-term efficacy, safety and drug survival of ustekinumab in a Spanish cohort of patients with moderate to severe plaque psoriasis. Dermatology 2015;230:46-54. https://doi.org/10.1159/000366499
- Menter A, Thaci D, Papp KA, Wu JJ, Bereswill M, Teixeira HD, et al. Five-year analysis from the ESPRIT 10-year postmarketing surveillance registry of adalimumab treatment for moderate to severe psoriasis. J Am Acad Dermatol 2015;73:410-419.e6. https://doi.org/10.1016/j.jaad.2015.06.038
- Kimball AB, Papp KA, Wasfi Y, Chan D, Bissonnette R, Sofen H, et al. Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study. J Eur Acad Dermatol Venereol 2013;27:1535-1545. https://doi.org/10.1111/jdv.12046
- Vergou T, Moustou AE, Antoniou C. Five-year experience with ustekinumab for psoriasis: real-life data of a single centre. J Eur Acad Dermatol Venereol 2017;31:e40-e41. https://doi.org/10.1111/jdv.13658
- Marinas JE, Kim WB, Shahbaz A, Qiang JK, Greaves S, Yeung J. Survival rates of biological therapies for psoriasis treatment in real-world clinical practice: a Canadian multicentre retrospective study. Australas J Dermatol 2018;59:e11-e14. https://doi.org/10.1111/ajd.5_12815
- Warren RB, Smith CH, Yiu ZZN, Ashcroft DM, Barker JNWN, Burden AD, et al. Differential drug survival of biologic therapies for the treatment of psoriasis: a prospective observational cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). J Invest Dermatol 2015;135:2632-2640. https://doi.org/10.1038/jid.2015.208
- Arnold T, Schaarschmidt ML, Herr R, Fischer JE, Goerdt S, Peitsch WK. Drug survival rates and reasons for drug discontinuation in psoriasis. J Dtsch Dermatol Ges 2016;14:1089-1099. https://doi.org/10.1111/ddg.13152
- Jacobi A, Rustenbach SJ, Augustin M. Comorbidity as a predictor for drug survival of biologic therapy in patients with psoriasis. Int J Dermatol 2016;55:296-302. https://doi.org/10.1111/ijd.12879
- Staidle JP, Dabade TS, Feldman SR. A pharmacoeconomic analysis of severe psoriasis therapy: a review of treatment choices and cost efficiency. Expert Opin Pharmacother 2011;12:2041-2054. https://doi.org/10.1517/14656566.2011.590475